Johnson & Johnson
1Q Revenues: $20.0 billion (flat)
1Q Earnings: $3.7 billion (-14%)
Comments: Pharmaceutical sales were $10.2 billion in the quarter, up 4% driven by driven by STELARA, up 32% to $1.4 billion, IMBRUVICA, up 34% to $784 million, DARZALEX, up 46% to $629 million, TREMFYA, with sales of $217 million, INVEGA SUSTENNA, up 14% to $790 million, PREZISTA, up 10% to $523 million, partially offset by declines in REMICADE, down 21% to $1.1 billion, and ZYTIGA, down 20% to $679 million.